Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQ B3525

Drug Profile

TQ B3525

Alternative Names: TQ-B3525

Latest Information Update: 15 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Developer Chia Tai Tianqing Pharmaceutical Group; Peking University People's Hospital
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Follicular lymphoma
  • Phase II Cervical cancer; Endometrial cancer; Mantle-cell lymphoma; Ovarian cancer
  • Phase I/II Chronic lymphocytic leukaemia; Non-small cell lung cancer; Osteosarcoma
  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Follicular lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 Dec 2023 Preregistration for Follicular lymphoma (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (PO) (SEC file 2023- HUTCHMED)
  • 31 Dec 2023 National Medical Products Administration (NMPA) accepts NDA for TQ-B3525 for follicular lymphoma for review (SEC file 2023- HUTCHMED)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top